A judge dismissed lawsuits filed by 37 different municipal governments pertaining to opioid drugmakers being sued in the state of Connecticut.
Privately held Pear Therapeutics said the company raised $64 million from investors, including Singapore’s Temasek Holdings, weeks after launching a mobile app for treating patients with substance use disorder.
A former executive at Insys Therapeutics Inc. pleaded guilty to participating in a scheme to bribe doctors to prescribe the company’s powerful opioid medication and entered into a deal to cooperate with prosecutors.
The FDA announced sweeping new restrictions on flavored tobacco products, including electronic cigarettes popular among teenagers in an effort to prevent a new generation of nicotine addicts.
State officials from New Jersey took aim at Johnson & Johnson subsidiary Janssen by filing a lawsuit pertaining to the marketing of opioids.
A growing number of publicly funded programs face a financial crunch as U.S. states jump at the chance to collect revenue through legal sports betting, while largely ignoring the need to spend more tackling gambling addiction.
Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.
Indivior Plc slashed full-year 2018 revenue expectation for the injectable opioid addiction drug Sublocade, sending the company’s shares tumbling more than 16 percent.
The U.S. Senate overwhelmingly supported a new bill aimed at opioid abuse and other addictive drugs.
Concentric Analgesics Inc. announced today that the clinical-stage biopharmaceutical company received Breakthrough Therapy designation from the U.S. Food and Drug Administration for CA-008 in post-surgical pain.